"Medicare-Approved Weight-Loss Injection Wegovy Offers Heart Disease Risk Reduction"
The weight-loss jab Wegovy, also known as semaglutide, has been approved by US regulators as a treatment for heart disease after a major trial showed it could reduce the risk of heart attack or stroke in people with obesity by around 20%. The drug, which suppresses appetite and boosts insulin production, is already available to eligible individuals in the UK and may potentially be accessible to thousands more with heart disease in the future. Experts believe it could eventually be used similarly to statins for preventing heart attacks and strokes, and the company behind the drug has applied for a similar update in the UK.